The experimental drug is similar to the Boston-based company’s recently approved pill Journavx but could potentially be given ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced topline results from its recently completed Phase 2, ...

Vertex Pharmaceuticals has hit a snag in its efforts to follow up non-opioid pain reliever Journavx (suzetrigine). | Vertex ...

Vertex Pharmaceuticals swung to a profit and logged higher sales in the second quarter, as more people used its cystic-fibrosis drug and the biotechnology company began rolling out new therapies.

Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with ...

Vertex Pharmaceuticals' stock fell in post-market trading Monday, after the company said it would not progress a next-generation pain treatment into advanced testing. Shares slid 14% to $407.30.

The U.S. FDA names Sean Keveney as chief counsel, overseeing legal matters. Vertex Pharmaceuticals faces setbacks after a trial failure for a pain drug. Florida reports 21 E. coli cases linked to raw ...

Vertex (VRTX) delivered earnings and revenue surprises of +6.60% and +2.59%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Analysts expect the Boston, Massachusetts-based company to report quarterly earnings at $4.25 per share, versus a year-ago ...

BOSTON - Vertex Pharmaceuticals (NASDAQ: VRTX) shares tumbled 8.7% after the company announced its experimental pain drug VX-993 failed to meet the primary endpoint in a Phase 2 clinical trial, ...

Vertex Pharmaceuticals beat Wall Street estimates for quarterly results on Monday, helped by demand for its new cystic ...

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...